ナブメトン
4-(6-メトキシナフタレン-2-イル)-2-ブタノン · 1-(6-メトキシ-2-ナフチル)-3-ブタノン · レリフェン · 2-(3-オキソブチル)-6-メトキシナフタレン · 4-(6-メトキシ-2-ナフチル)-2-ブタノン · レラフェン · ナブメトン · 4-(6-メトキシナフタレン-2-イル)ブタン-2-オン
識別子と物理属性
| CAS No. | 42924-53-8 |
|---|---|
| 分子式 | C15H16O2 |
| 平均分子量 | 228.29 g/mol |
| 単同位体質量 | 228.11502975 g/mol |
| SMILES | COc1ccc2cc(CCC(C)=O)ccc2c1 |
| InChIKey | BLXXJMDCKKHMKV-UHFFFAOYSA-N |
| PubChem CID | 4409 |
| ChEMBL | CHEMBL1070 |
| ChEBI | CHEBI:7443 |
| EC No. | 641-917-1 |
| DTXSID | DTXSID4045472 |
| 現地名 | ナブメトン |
化学・物理的性質
| XLogP | 3.1 |
|---|---|
| 極性表面積 | 26.3 |
| 水素結合供与体数 | 0 |
| 水素結合受容体数 | 2 |
| 回転可能結合数 | 4 |
| 重原子数 | 17 |
| 形式電荷 | 0 |
| 複雑度 | 262 |
| 医薬品 | PharmaceuticalsPharmaceuticals -> Listed in ZINC15 |
| LogP（分配係数） | 3.13.45 |
| 溶解度 | Practically insoluble1.93e-03 g/Lアルコールまたはクロロホルムに可溶6mg/L(22.5℃) |
| Human Drugs | Breast FeedingLactationMilk, HumanAnalgesic AgentsAnti-inflammatory Agents, NonsteroidalFDA approved drugs -> Active ingredientPharmaceuticals |
| 融点 | 78-8280 °C80-810C |
| Physical Description | Solid |
| Collision Cross Section | 148.38 Ų [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]148 Ų [M+H]+ [CCS Type: TW |
| 沸点 | 330.1°C (rough estimate) |
| 密度 | 1.0657 (rough estimate) |
| 屈折率 | 1.5542 (estimate) |
| 貯蔵条件 | Sealed in dry,2-8°C |
| 外観・状態 | Solid |
| 色 | 白い |
| BCS Class | 2/4 |
| 主な用途 | 法医学と毒物学医薬品（低分子化合物）獣医 |
| InChI | InChI=1S/C15H16O2/c1-11(16)3-4-12-5-6-14-10-15(17-2)8-7-13(14)9-12/h5-10H,3-4H2,1-2H3 |
| InChIKey | BLXXJMDCKKHMKV-UHFFFAOYSA-N |
| SMILES | CC(=O)CCC1=CC=C2C(=C1)C=CC(OC)=C2 |
| CAS データベース | 42924-53-8(CAS DataBase Reference) |
| NISTの化学物質情報 | Nabumetone(42924-53-8) |
化学的特性
White Powder
安全性と法規制
| GHS 分類 | This chemical does not meet GHS hazard criteria for 14.3% (1 of 7) of reports.WarningH302 (42.9%): Harmful if swallowed [Warning Acute toxicity, oral]P203, P260, P261, P264, P264+P265, P270, P271, P273, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P317, P318, P319, P321, P330, P332+P317, P337+P317, P362+P364, P391, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 7 reports by companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| Hazard Classes and Categories | Acute Tox. 4 (42.9%) |
| Protective Action Criteria (PAC) | 1.0 [mg/m3]11 [mg/m3]66 [mg/m3] |
| Hepatotoxicity | Prospective studies show that 1% to 5% of patients taking nabumetone experience at least transient serum aminotransferase elevations. These may resolve even with drug continuation. Marked aminotransferase elevations (above 3 times ULN) occur in 0.5% of patients, a rate similar to that in placebo treated controls. Clinically apparent liver injury with jaundice from nabumetone is rare and in large clinical trials, no instances of acute liver injury with jaundice were reported. Since its approval and release, nabumetone has been reported to cause rare instances of serious hepatic adverse events (~1.3 per million prescriptions), but there have been no cases of clinically apparent liver injury due to nabumetone described in the published literature. Furthermore, nabumetone is not mentioned as a cause in large case series on drug induced liver injury or acute liver failure. Thus, the latency, clinical features and outcome of nabumetone induced liver injury have not been described and clinically apparent hepatotoxicity due to nabumetone must be very rare. |
| Drug Induced Liver Injury | Drug Induced Liver Injury Rank (DILIrank 2.0)NabumetoneAmbiguous-DILI-concern3Warnings & precautionsDOI:10.1016/j.drudis.2016.02.015 |
| Effects During Pregnancy and Lactation | ◉ Summary of Use during Lactation |
| 水環境危害等級（WGK） | 2 |
用途
説明
Nabumetone is a non-acidic, nonsteroidal antiinflammatory agent formally related to naproxen. Its main circulating metabolite is 6-methoxy-2-naphthylacetic acid (α-nornaproxen). Administered once daily (Tsub>1/2 * 30 hrs), nabumetone is reported to be effective in the treatment of rheumatoid and osteoarthritis.
使用
Nabumetone is an anti-inflammatory and antibacterial agent (1). A non-steroidal anti-inflammatory prodrug used for treatment of inflammatory and degenerative rheumatic diseases.
一般的な説明
Nabumetone (Relafen), a nonacidic NSAID prodrug, isclassified as an arylacetic acid, because it undergoes rapidhepatic metabolism to its active metabolite, 6-methoxy-2-naphthylacetic acid. Similar to the other arylacetic aciddrugs, it is used in short- or long-term management of RAand OA. Being nonacidic, it does not produce significantprimary insult to the GI mucosa lining and also has no effecton prostaglandin synthesis in gastric mucosa, thus producingminimum secondary GI damage when comparedwith other conventional NSAIDs.